ReviewMolecules (Basel, Switzerland)2022
Metallo-Drugs in Cancer Therapy: Past, Present and Future.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 180 citations in OpenAlex.
- Acoustically Activatable Drug-Loaded Nanodroplets for Mechanochemical Therapy in Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- A spectroscopic andRSC advances · 2026Article
- 6-(2-Aminoethyl)-6Biomolecules · 2026Article
- Employment of the fluorescent probe hydroxy-naphthyl-methylbenzoxazole-based dye and its combination with fluorescent silica nanoparticles as potential heavy metal-targeting systems: results and troubleshooting in Cd-polluted environments.Analytical and bioanalytical chemistry · 2026Article
- Leveraging Morphological Profiling for Mechanistic Elucidation of Metal-Based Anticancer Compounds.JACS Au · 2026Article
- Recent Advances in Anticancer Activity of Gold(I) Complexes.Biomedicines · 2026Review
- Mitochondria-Targeting Metal Complexes: Design Principles, Mechanisms of Action, and Translational Perspectives.Biomolecules · 2026Review
- In Vitro Cytochrome P450 Interaction Profile and ADME Characterisation of Gold(I)-Triphenylphosphine Complexes with 6-Alkoxy-9-deazapurine Ligands.Pharmaceutics · 2026Article
- Oxaliplatin-associated nephrotoxicity: clinical patterns, renal pharmacokinetics, and mechanistic insights.Cancer chemotherapy and pharmacology · 2026Review
- ERα-Independent Activity of Tamoxifen-Based Transition Metal Hybrids in Triple-Negative Breast Cancer Models In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2026Article
- Competitive LC-MS/MS assay to investigate protein metalation dynamics.Inorganic chemistry frontiers · 2026Article
- Palladium(II) Complexes with Chloro-Substituted Salicyl Schiff Bases: Exploring Multimodal Anticancer Mechanisms and Catalase Inhibition.Molecules (Basel, Switzerland) · 2026Article
- Novel Silver(I) and Gold(I) N-Heterocyclic Carbene Complexes Induce ROS-Dependent Autophagic Cell Death in Human Hepatoma Cell Line HepG2.Chemical biology & drug design · 2026Article
- Quinoxaline Derivatives in Cancer Therapy: Insights into Mechanisms of Action and Therapeutic Applications.Biomolecules & therapeutics · 2026Review
- Nature-Inspired Gold(I) Complexes as Anticancer Agents: Ligand Design, Structure-Activity Relationships, and Mechanisms.Cancers · 2026Review
- Ru-Based NSAIDs as Potential Anticancer Therapeutics.Molecules (Basel, Switzerland) · 2026Article
- A Ru(ii)-arene complex with promising anti-Aβ activity.RSC advances · 2026Article
- Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy.Pharmaceutics · 2026Review
- Eutectogels as Delivery Media for Therapeutic Metal Complexes: What Are the Benefits?Gels (Basel, Switzerland) · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer treatments which include conventional chemotherapy have not proven very successful in curing human malignancies. The failures of these treatment modalities include inherent resistance, systemic toxicity and severe side effects. Out of 50% patients administrated to chemotherapy, only 5% survive. For these reasons, the identification of new drug designs and therapeutic strategies that could target cancer cells while leaving normal cells unaffected still continues to be a challenge. Despite advances that have led to the development of new therapies, treatment options are still limited for many types of cancers. This review provides an overview of platinum, copper and ruthenium metal based anticancer drugs in clinical trials and in vitro/in vivo studies. Presumably, copper and ruthenium complexes have greater potential than Pt(II) complexes, showing reduced toxicity, a new mechanism of action, a different spectrum of activity and the possibility of non-cross-resistance. We focus the discussion towards past, present and future aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.